ArticleEuropean journal of neurology2025
Glycolipid Antibodies in Patients With Chronic Idiopathic Axonal Polyneuropathy and Gluten Neuropathy.
Article in European journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Glycolipid Antibodies in Patients With Chronic Idiopathic Axonal Polyneuropathy and Gluten Neuropathy.European journal of neurology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the presence of IgM and IgG antibodies in the serum of patients with chronic idiopathic axonal polyneuropathy (CIAP) and gluten neuropathy (GN) using a newly developed microarray technique.
methodsSera from 42 CIAP patients, 32 GN patients, and 79 healthy controls were tested for IgM and IgG antibodies against 16 single glycolipids and their 120 heteromeric complexes. Positivity rates were analyzed using the 95th percentile from controls.
resultsIgM positivity against 8 heteromeric complexes was more frequent in CIAP patients (16.7% to 28.6%) compared to controls, while GN patients showed higher rates (18.8% to 46.9%) across 15 complexes. GN patients had a higher rate of IgM positivity against the GM2:GT1b complex than CIAP patients (46.9% vs. 21.4%). IgG antibodies against seven antigens were also more prevalent in CIAP (16.7% to 26.2%) and GN patients (18.8% to 28.1%) than controls. GN patients showed a higher rate of IgG positivity against the GM1:Sulfatide complex than CIAP patients (15.6% vs. 0%).
conclusionsThis is the first study to report increased antibody detection rates against peripheral nerve glycolipids, both individually and in complexes. The findings suggest that a significant proportion of CIAP and GN patients may have an autoimmune pathogenesis, potentially targetable by immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.